Back to top

Truist Financial Sticks to Their Buy Rating for Genmab (GMAB)

Truist Financial analyst Gregory Renza maintained a Buy rating on Genmab today and set a price target of $40.00. According to TipRanks, Renza is a ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Genmab A/S Sponsored ADR (GMAB)